Plavix Articles
Sanofi beats forecasts: 2nd-qtr sales up 19.4%
26 July 2004
US branded drug prices "rose faster after MMA"
12 July 2004
B-MS reports 1st-qtr earnings jump 22%
3 May 2004
Sanofi's sales +18% to 2.2B euros for 1st-qtr
26 April 2004
Aventis' battle against Sanofi bid; Editorial
26 April 2004
Aventis makes formal proposal to Novartis
12 April 2004
Detailing rejection of Sanofi bid, Aventis says it is opportunistic, under-values firm
15 March 2004
Aventis appeals over Sanofi bid decision
1 March 2004
Sanofi-Synthelabo reveals R&D pipeline with nine compounds in Ph III
23 February 2004
Aventis still argues against Sanofi bid
16 February 2004
20% pharma sales rise boosts B-MS profits
9 February 2004
Aventis rejects Sanofi-Synthelabo's $60 billion hostile bid
2 February 2004
Sanofi-Synthelabo's 2003 sales up 15.6%
26 January 2004
Sanofi shareholders back out of pact
8 December 2003
B-MS ups forecast on strong 3rd quarter
3 November 2003
Sanofi sales strong but below expectations
27 October 2003
Sanofi-Synthelabo ups forecast on strong 1st-half, but fears persist over key patent
8 September 2003
Sanofi raises full-year earnings forecast
8 September 2003
UPDATE: B-MS beats forecasts in 2nd qtr
4 August 2003
B-MS beats forecasts in 2nd qtr
4 August 2003
Sales up 14% at Sanofi-Synthelabo in 1st half
28 July 2003
Profits down 11% at B-MS in first quarter
5 May 2003
Sanofi-Synthelabo 1st qtr below consensus
5 May 2003
Stock Commentary - Europe
17 March 2003
Boeh Ingelheim starts two mega-trials
24 February 2003
53.7% US sales leap boosts Sanofi-Synthelabo
27 January 2003
B-MS provides 2003 earnings guidance
27 January 2003
Sanofi, Aventis merger only matter of time?
20 January 2003
New Plavix patent for Sanofi-Synthelabo
19 August 2002
Sanofi-Synthelabo 1st-half sales up 14.8%
29 July 2002
Sanofi-Synthelabo 1st-half sales up 14.8%
29 July 2002
B-MS turnover down 14% in 2nd quarter
29 July 2002
NEJM article questions role of Plavix
17 June 2002
NEJM article questions role of Plavix
17 June 2002
Stock Commentary - Europe
10 June 2002
MATCH trial enrolment with 7,600+ patients completed
10 June 2002
Plavix defense extends to include Dr Reddy's
10 June 2002
Somatropin OK for GH deficiency: UK NICE
3 June 2002
Stock Commentary - Europe
15 April 2002
France's top-selling Rx drugs in 2001
15 April 2002
Sanofi-Synthelabo files against Apotex
1 April 2002
US guidelines endorse Plavix' role in angina
25 March 2002
Stock Commentary - Europe
4 March 2002
New NICE appraisal program goes for one-month consultation
25 February 2002
Generic threats to Sanofi-Synthelabo's major antithrombotic Plavix?
18 February 2002
Stock Commentary - Europe
18 February 2002
Update: Akzo and Sanofi-Synthelabo's Arixtra debuts in USA for DVT
18 February 2002
Stock Commentary - Europe
28 January 2002
France's Sanofi-Synthelabo continues to outperform competitors
26 October 2001
B-MS earnings driven by Glucophage
24 October 2001
Sanofi to invest 30m euros in French site
11 October 2001
Stock Commentary - Europe
11 October 2001
Pharma DTC web sites failing to address consumer needs, says study
14 September 2001
Stock Commentary - Europe
13 September 2001
FDA fast-tracks CURE data review for Plavix
10 September 2001
Sanofi-Synthelabo first-half net income rises 50% - UPDATE
6 September 2001
Sanofi-Synthelabo net income jumps 50%
31 August 2001
Sanofi-Synthelabo 1st-half sales up 15%
30 July 2001
Sanofi-Synthelabo 1st-half sales up 15%
27 July 2001
Sanofi-Synthelabo to buy out Indian JV
30 May 2001
Sanofi-Synthelabo profits to rise 30%
24 May 2001
B-MS 1st-qtr pharma sales up 8% at $3.7B
26 April 2001
Blockbusters propel Sanofi-Synthelabo
25 April 2001
Update: CURE data to boost clopidogrel sales
22 March 2001
Stock Commentary - Europe
22 March 2001
Sanofi-Synthelabo net earnings increase 54% for 2000
21 February 2001
Sanofi-Synthelabo sales rise 10.3%
29 January 2001
Sanofi-Synthelabo sales rise 10.3%
26 January 2001
Bristol-Myers Squibb's "solid year" sees net earnings rise 13%
25 January 2001
Stroke prevention emerges from heart disease
10 January 2001
Chinoin exclusive supplier for Sanofi-Synthelabo's Plavix
29 November 2000
Cravit driving growth at Daiichi
14 November 2000
Sanofi-Synthelabo sales up 11.4%
25 October 2000
B-MS net earnings increase 13%
23 October 2000
Sanofi-Synthelabo - peaking early?
20 October 2000
B-MS focuses on intense growth and reveals product pipeline
2 October 2000
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
